Posted by Michael Wonder on 01 Aug 2022
HSE weighs up impact of obesity drug that costs 250 Euros a month
31 July 2022 - Health authorities are evaluating whether a game changing new obesity drug should be used in Ireland because of the high cost it would impose on the healthcare budget.
Semaglutide, marketed as Wegovy and approved by the EMA in March, can reduce body weight by 15 %, but may cost about €250 a month per patient.
